Clinical Trial

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-08-30; most recent amendment 2026-03-13.
Status change: Not Yet Recruiting → Recruiting 2023-12-14
Trial Details
NCT Number NCT06026319
Lead Sponsor Marcela V. Maus, M.D.,Ph.D.
Conditions Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), High-grade B-cell Lymphoma +2 more
Enrollment 24 participants
Start Date 2023-10-26
Primary Completion 2027-01-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-16